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A B S T R A C T
Aims: AML (Acute myeloid leukemia) is characterized as a heterogeneous cancer. Chemokines play fundamental
roles in the onset, progression cellular, migration, survival and improvement of AML therapy outcomes. The
CCR5 receptors together with their ligands have indirect eﬀects on the progression of cancer. In the present
study, we have decided to investigate the impact of chemotherapy on the expression of CCR5 and its related
ligands (CCL5, CCL4 and CCL3).
Main methods: In this study, peripheral blood and bone marrow specimens were collected prior and post the ﬁrst
stage of (7 + 3) chemotherapy from 25 AML-M4/M5 patients. The expression of CCR by Lymphocytes in per-
ipheral blood was examined by ﬂow cytometry and QRT-PCR. The serum levels of chemokines were measured by
ELISA.
Key ﬁndings: There was not observed leukemic blast cells in peripheral blood smear at post ﬁrst stage of che-
motherapy. We found that the expression of CCR5 was attenuated in patients post the ﬁrst stage of chemotherapy
and the healthy control subjects. We have also observed that the serum levels of chemokines were elevated in
AML patients prior to chemotherapy. Although in post-chemotherapy stage, only CCL3 was found to reach to the
baseline level, CCL5 and CCL4 have not returned to the basal level and were signiﬁcantly higher than healthy
control subjects.
Signiﬁcance: The current chemotherapy protocol was not able to completely inhibit CCL5 and CCL4. In con-
clusion, our ﬁndings in harmony with previous studies suggest that inhibition of chemokines along with che-
motherapy in AML patients may aid therapy.
1. Introduction
Acute myeloid leukemia (AML) was initially deﬁned as an ag-
gressive and heterogeneous bone marrow (BM) malignancy. Therapy of
AML includes intensive chemotherapy, either alone or in combination
with allogeneic stem cell transplantation [1–3]. Chemokines alongside
with their cognate receptors are pivotally involved in the pathogenesis
of AML [4,5]. It has also been well evidenced that leukemic blasts re-
present abnormal degrees of responsiveness to cytokine stimulation,
however, they are most often able to produce cytokines [6].
Likewise, other chemokine receptors, the CC chemokine receptor 5
(CCR5) which is now known as CD195 ﬁts within the trimeric guanine
nucleotide-binding protein-coupled, seven transmembrane receptors
superfamily. The CC chemokine ligands CCL5, CCL4 and CCL3 bind to
the CCR5 for their functional activity. All of these mediate oriented
migration of cancer cells in parallel with contributing in processes of
proliferation and survival of these cell types [5,7,8]. Additionally, it has
been documented that CCR5 contributes to the events of tumor pro-
gression in several hematological cancers, including AML, chronic
myeloid leukemia (CML) and multiple myeloma (MM) [9]. The native
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human AML cells have the tendency to generate CCL5 and expresses
CCR5 and the CCL5/CCR5 interaction axis modulates metabolic events
within the tumor microenvironment while tumor onset is going on to
promote tumorgenesis [10,11].
Increased levels of CCL4 and CCL3 were observed in the bone
marrow of patients who were suﬀering from CML (chronic myeloid
leukemia) [12]. In more recent attempts, was demonstrated that the
mouse tumor-inﬁltrated granulocytic and monocytic/myeloid-derived
suppressor cells are able to produce high levels of CCR5 chemokine
ligands including, CCL5, CCL4, and CCL3, all of which are responsible
for the recruitment of Tregs (T regulatory cells). Therefore, a novel
immune modulatory strategy could probably be achieved for cancer
therapy by blocking of CCL5/CCR5 interaction axis [8]. Regardingly,
modulation of cytokine network could be considered as a path to
overcome therapy resistance. Further most, to improve the selectivity of
AML treatment, for controlling the overall therapy-associated toxicity
as well as ameliorate outcomes of AML treatment by approaching the
modulation of cytokine networks in all of AML age groups [4]. More-
over, it has also been well documented that CCL5/CCR5 axis was able
to eﬀectively aﬀect the development of tumor cells, and hence the axis
has the capacity to be considered as a promising tool for the estab-
lishment of anticancer compounds [13,14]. In more recent studies, the
CCL5/CCR5 axis was only examined in leukemia cells, nonetheless,
CCR5 is predominantly expressed by several other cell types, including
T regulatory cells, macrophages, dendritic cells and eosinophil's as well
[4,8]. According to the aforementioned introductory comments, mod-
ulation of cytokine-dependent processes in AML could be considered as
an appropriate therapeutic approach. Therefore, we sought to evaluate
the eﬀects of (7 + 3) therapy protocol which is currently applied as a
chemotherapy regimen (for treatment of AML, worldwide) on CCL3-
CCL4-CCL5/CCR5 functional axes. We have also examined the expres-
sion of CCR5 on Lymphocytes population in AML patients along with its
ligands prior and post the ﬁrst stage of chemotherapy in these patients.
2. Material and methods
2.1. Study subjects and specimen collection
This case-control study was approved by the ethical committee of
the Kerman University of Medical Sciences with the approval code
IR.KMU.REC.1395.598. Informed written consent was also obtained
from each participant.
Specimens were collected from 25 patients suﬀering from AML (M4
and M5) from 2017 to 2018 in the Shahid Bahonar University hospital
of Kerman, Iran. AML patients were classiﬁed according to the FAB
(French–American–British) classiﬁcation. FAB subtype was further
conﬁrmed by immune phenotypic proﬁling (CD13, CD14, CD33, CD34,
CD64, CD117 and HLA-DR). All of the studied patients received similar
(7 + 3) current chemotherapy regimen and patients who had received
a diﬀerent chemotherapy protocol were excluded from the study.
Peripheral blood smear (PBS) and bone marrow smear were both pre-
pared from patients at the time of diagnosis and post the ﬁrst stage of
chemotherapy (following the fourth week of complete chemotherapy
when complete blood count (CBC) was approximately normal) and
percentage of blast cells was calculated.
A volume of 5 mL blood sample was taken from each patient prior
initiation of chemotherapy and after the ﬁrst stage of chemotherapy
(following the fourth week of complete chemotherapy when complete
blood count (CBC) was approximately normal) also serum samples were
isolated and stored at −80 °C until being used in experiments.
Participants of the healthy control group were selected from Kerman
population and were then matched with AML patients with regard to
demography, including age and sex status.
2.2. Total RNA isolation and cDNA production
Total RNA was isolated from the buﬀy coat of harvested samples
using Trizol Reagent (Invitrogen, USA) according to the instructions of
the manufacturer. Both, the quality and purity of isolated RNA samples
were evaluated by agarose gel electrophoresis and measurement of
optical density (A260/A280 ratio) by applying a NanoDrop 1000
Spectrophotometer (Wilmington, DE, USA), respectively. To eliminate
the genomic DNA from RNA preparations, DNase I, RNase-free kit from
Thermo (Thermo Scientiﬁc, USA) was employed, according to the
manufacturer instructions.
The reverse transcription (RT) reaction was conducted using the
Revert Aid First Strand complementary DNA (cDNA) Synthesis kit
purchased from Thermo (Thermo Scientiﬁc, USA).
2.3. Performing the quantitative real-time PCR (QRT-PCR)
QRT-PCR was performed by adding 5 μL of Real Q Plus 2× Master
Mix Green (Ampliqon, DK), 1 μL of the cDNA product, 0.5 μL of forward
and reverse primers (0.5 μL equal to 10 pmol), and reaction mixture
solution reached to a volume of 10 μL by adding 3 μL of nuclease-free
water. The reaction mixtures were further incubated for an initial ac-
tivation step at 95 °C for 15 min and followed by 40 cycles including a
denaturation step at 95 °C for 15 s and a combined annealing/elonga-
tion step at 60 °C for 60 s. The reaction was performed in the Rotor-
Gene Q, Real-time PCR System (Qiagen, USA). A melting curve analysis
was performed for veriﬁcation of the speciﬁcity of the products. The
fold induction or repression was measured relative to the control and
calculated further adjusting with GAPDH as the housekeeping reference
gene using the comparative Ct (2 − ΔΔCT) method. The sequences for
primers used in QRT-PCR are (all in 5_ to 3_direction) as follows:
GAPDH Forward primer, GAAGGTGAAGGTCGGAGTC; GAPDH Reverse
primer, GAAGATGGTGATGGGATTTC; CCR5 Forward primer, ATGTG
AAGCAAATCGCAGCC; CCR5 Reverse primer, GCCAGGTTGAGCAGGT
AGAT.
2.4. Flow cytometry analysis
In order to detect the expression of CCR5 on the membrane of
peripheral blood Lymphocytes in AML patients and healthy controls,
peripheral blood samples were treated with the indicated monoclonal
antibodies and their isotype-matched negative control according to the
manufacturer's instructions. Brieﬂy, 5 μL of PE-conjugated anti-CD195
(BD, USA) was added to 50 μL peripheral blood samples, and after 30-
minute incubation, red blood cells lysis solution (BD, USA) was used for
RBC lysis. Cells (1 × 104) were analyzed by Partec system model PAS.
Lymphocytes population was gated by forward scatter and side scatter.
Percentage of CCR5 on evaluated cells was obtained using the provided
software (Flow Max) in the Partec system model PAS.
2.5. Chemokines assay
The serum levels of CCL5 (RANTE), CCL4 (MIP-1β) and CCL3 (MIP-
1α) were measured by ELISA using kits purchased from R&D systems,
UK, in patients and healthy subjects, immediately further collection and
serum isolation. All of assays were conducted according to manufac-
turer's guidelines. The detection limit for each kit was as follow: 6.6 pg/
mL for CCL5, 11 pg/mL for CCL4, 10 pg/mL for CCL3.
2.6. Statistical analysis
Data were analyzed using SPSS software version 22 (SPSS Inc.,
Chicago, IL, USA).
Quantitative data were presented as Mean ± SEM. For comparison
of the underlying factors, two sample t-Test and Paired t-Test were used.
The diﬀerences have been considered, only if P < 0.05.
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3. Results
3.1. The response of AML patients to the chemotherapy
We have observed that AML patients have attained a partial re-
sponse to chemotherapy that was seen (7.9 ± 1.2%) of blast cells in
BM post ﬁrst stage of chemotherapy also was not observed blast cells in
PBS at post ﬁrst stage of chemotherapy. Clinical and demographic
characteristics of AML patients and healthy control group are shown in
Table 1.
3.2. Expression of CCR5 by Lymphocytes population
We sought to ﬁnd whether if CCR5 receptor was expressed by
Lymphocytes population in AML patients post the ﬁrst stage of che-
motherapy in comparison with healthy control group. We have initially
detected the mRNA expression of CCR5 by QRT-PCR. We found that the
expression of CCR5 was low in all of AML patients at post ﬁrst stage of
chemotherapy and all members of the healthy control group. The
comparative analysis of CCR5 expression indicated that patients had an
approximate similarity with the healthy control group, however, the
expression of CCR5 was not signiﬁcantly diﬀered in studied group
(P ˃ 0.05) (Fig. 1). We have then veriﬁed the expression of CCR5 by
ﬂow cytometry and we found similar results with the QRT-PCR results
(Figs. 2, 3).
3.3. Analysis of the serum levels of chemokines
When we have analyzed, the serum level of CCL5 was found that it
was considerably increased in AML patients prior chemotherapy and
post the ﬁrst stage of chemotherapy, however, the serum level of CCL5
has signiﬁcantly decreased post ﬁrst stage of chemotherapy. Although,
the serum level of CCL5 has remarkably been decreased further che-
motherapy in AML patients however, it has not backed to its basal level
(the CCL5 level in healthy controls) (Table 2 and Fig. 4A). We have also
observed that as similar as CCL5, the serum level of CCL4 was increased
in AML patients prior to chemotherapy and the further ﬁrst stage of
chemotherapy. The serum level of CCL4 has signiﬁcantly decreased post
ﬁrst stage of chemotherapy. Again, CCL4 was remarkably reduced in
AML patients post-chemotherapy but it has not reached to the level
which was observed in healthy control subjects (the basal level)
(Table 2 and Fig. 4B). In the present study, we have found that prior
chemotherapy AML patients had a very high level of CCL3 while post
ﬁrst stage of chemotherapy CCL3 has signiﬁcantly decreased to the
baseline level as similar as the level which was observed in the healthy
control group. There was not a signiﬁcant diﬀerence between AML
patients post ﬁrst stage of chemotherapy and healthy control group
with regard to CCL3 serum level (Table 2 and Fig. 4C). Our results
indicated that the current chemotherapy regimen (7 + 3) in patients
suﬀering from AML with monocytic diﬀerentiation in the ﬁrst stage of
chemotherapy has not aﬀected the expression of CCR5 by Lymphocytes
population, however, it has signiﬁcantly down-tuned the serum mea-
sures of CCL5, CCL4, and CCL3 chemokines. However, only CCL3 was
found to reach the baseline level compared to the healthy control
group, but CCL5 and CCL4 have not backed to their basal level.
Therefore, this chemotherapy protocol has not completely inhibited
CCL5 and CCL4 (Fig. 4).
Table 1
Clinical and demographic characteristics of AML patients and healthy controls.
Age (MEAN ± SEM) Gender M4/M5 % Blast cells in BMa
(mean ± SEM)
% Blast cells in PBa
(mean ± SEM)
WBC count in PBb
(mean ± SEM)
Extramedullary
involvement
Patient 41.45 ± 4.7 12 M/13 F 16/9 47 ± 5.8 46.45 ± 8.6 8360 ± 1158c No
Healthy control 40 ± 3.2 10 M/15 F – – – 8050 ± 963 –
AML = Acute myeloid leukemia.
BM = bone marrow.
PB = peripheral blood.
SEM = Standard Error of Mean.
a At the time of diagnosis.
b White blood cell (WBC) count in peripheral blood.
c Post ﬁrst stage of chemotherapy.
Fig. 1. Demonstrates the mRNA expression of CCR5 in AML
patients post chemotherapy (n = 9) and healthy controls
(n = 11). The quantitative real-time PCR using speciﬁc pri-
mers for CCR5 and GAPDH was performed. All values were
normalized against GAPDH. There was no statistically sig-
niﬁcant diﬀerence (P = 0.5025). Bar represent Mean ± SEM
of Healthy control = 0.2422 ± 0.057 and Mean ± SEM of
Post chemotherapy = 0.1713 ± 0.078.
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4. Discussion
Evidences are in favor of the concept that cancer cells are able to
establish changes in the chemokine system. Consequently, altered cyto/
chemokine network can disrupt activation of signaling pathways [4].
Depending on the tumor type, the stage and composition of immunity,
inhibition of chemokines or their receptors may have positive or de-
structive eﬀects on the development of the disease [13].
The current study was aimed to examine the eﬀects of frequent
chemotherapeutic regimen (7 + 3) on CCL3-CCL4-CCL5/CCR5 axes in
AML patients with monocytic diﬀerentiation.
Scientists reported that adaptive immune cells have undergone
changes after chemotherapy in AML patients [15]. Therefore, we have
evaluated CCR5 expression by Lymphocyte cells post ﬁrst stage of
chemotherapy and healthy control group. We have also examined
CCL5, CCL4 and CCL3 prior and post the ﬁrst stage of chemotherapy
and in healthy control group.
Regardingly, we found that the expression of CCR5 down-regulated
in Lymphocytes population of AML patients following the ﬁrst stage of
chemotherapy as well as members of the healthy control group,
Fig. 2. Demonstrates the expression of chemokine receptor in AML patients post chemotherapy and healthy subjects. Cells were stained with PE_conjugated MAb
CD195 and analyzed by ﬂow cytometry. Cells were gated based on side light and forward light scatter. Histograms represent the PE ﬂuorescence obtained using
isotype-matched murine MAb as negative control (A), MAb against CD195 in a patient post chemotherapy (B) and Healthy control (C). R1 gates Lymphocyte cells and
RN2 indicates the cells that express CD195.
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chemotherapy has not signiﬁcantly aﬀected the expression of CCR5 by
Lymphocytes population in peripheral blood of AML patients. Our re-
sults indicated that the serum levels of CCL5, CCL4, and CCL3 have
signiﬁcantly increased in AML patients with monocytic diﬀerentiation
compared to healthy subjects that proposing an inﬂammatory state
associated with the suppression of T cell-related immune response. This
is inconsistent with a recently published article that proposed a double-
faced cell mediated immunity in some disorders and malignancies, in-
cluding AML, which means that T cells exhibit stimulated phenotype,
while their activity has been suppressed [16]. In line with our study,
Astrid Marta Olsnes and colleagues evaluated the expression of CCL3
and CCL5 by AML blast cells and observed that these cell types produce
both of chemokines [17,18]. Additionally, Yang Wang et al. reported
that the serum level of CCL3 was increased in AML patients [19].
Our results, which indicated an elevation in CCL5, CCL4 and CCL3
in patients, were consistent with the previous studies.
CCL5 is considered as a molecular biomarker by which the presence
of tumor-dependent macrophages (TAM) could be conﬁrmed in tissue,
this chemokine has also the ability to enhance the expression of an-
giogenesis factors, including VEGF (Vascular endothelial growth factor)
[20]. Immune Suppressive Myeloid Cells (ISMCs) are described as a
negative immune regulator against the tumor. The CCL5/CCR5 axis
also pushes precursor cells into the bone marrow toward granular and
monocytic granulocyte group in tumorigenesis. These ISMCs them-
selves increase regulatory T cells, and subsequently the regulatory T
cells, however, they reduce TCD8+ cells that play a potential role
against tumor cells [14].
Furthermore, another ligand of CCR5 is CCL3 which has a direct
growth inhibitory eﬀect against normal hematopoietic stem/progenitor
cells (HSPCs) [21]. It also induces the proliferation of leukemia cells
[4,22]. In a study, investigators demonstrated that CCL3/CCR5 inter-
action axis is pivotally involved in the storage of AML blast cells in the
skin [18].
Koichi Takahashi et al. reported that a high concentration of CCL4
and CCL3 was associated with poor prognosis in patients with diﬀuse
large B cell lymphoma (DLBCL) [23].
Some investigations have suggested that elevated levels of CCL5,
CCL3 is associated with poor prognosis in AML also elevated level of
CCL4 is associated with poor prognosis in some disorders. Therefore,
controlling the expression chemokines in AML patients may aid treat-
ment and thus prevent the relapse of the disease by this fashion. Yuting
Ma and colleagues designed immunotherapy by a combination of a
vaccine, chemotherapy in addition to a Toll_like receptor3 agonist
(VCT) for non-treatable tumors such as melanoma and glioma. They
treated mice with VCT that had already been treated with CCL5. Their
results demonstrated that treatment was delayed because CCL5 had
recruited and caused accumulation of CCR5 expressing immune cells,
which are pivotally important for the development of the tumor. Thus,
taking together these observations may in a way conﬁrm that the in-
hibition of CCL5 may probably improve the therapeutic eﬀects of VCT
[13].
Secretion of cytokine by chemotherapy potently aﬀects host tissues
Fig. 3. Demonstrates the expression of CCR5 by Lymphocytes
population in patients post chemotherapy (n = 25) and
healthy control (n = 25). There was no statistically sig-
niﬁcant diﬀerence (P = 0.74). The results are from 1 × 104
cells ﬂow cytometry analysis. Bar represent Mean ± SEM of
Healthy control = 1.030 ± 0.2301 and Mean ± SEM of
Post chemotherapy = 0.9018 ± 0.3348.
Table 2
Serum levels of CCL5, CCL4 and CCL3 chemokines in AML patients and healthy control.
Serum levels of chemokines (pg/mL)a
mean ± SEM
Chemokine AML patients Healthy control
subjects
p-Valuesb
Prior-chemotherapy Post-chemotherapy Healthy control VS prior
chemotherapy
Healthy control VS post-
chemotherapy
Prior chemotherapy VS post-
chemotherapy
CCL5 1312 ± 100.5 442.2 ± 114.0 125.9 ± 3.680 P < 0.0001 0.0198 0.0002
CCL4 1414 ± 108.2 310.6 ± 18.37 130.8 ± 15.48 P < 0.0001 P < 0.0001 P < 0.0001
CCL3 888.4 ± 138.7 146.0 ± 6.279 151.5 ± 15.18 P < 0.0001 0.7886 0.0003
a pg/mL as measured by ELISA.
b
The diﬀerences have been considered, only if P < 0.05.
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Fig. 4. Demonstrates the serum levels of CCL5, CCL4 and CCL3 in AML patients. The chemokines serum levels were analyzed by ELISA.
Proﬁle A shows the serum levels of CCL5 in AML patients prior and post chemotherapy (n = 25) alongside with healthy controls (n = 25). There was signiﬁcant
diﬀerence in patients prior chemotherapy with healthy controls (***P ˂ 0.0001) and post chemotherapy with healthy controls (*P ˂ 0.05). Also there was signiﬁcant
diﬀerence in patients prior and post chemotherapy (**P ˂ 0.001).
Proﬁle B shows the serum levels of CCL4 in AML patients prior and post chemotherapy (n = 25) alongside with healthy controls (n = 25). There was signiﬁcant
diﬀerence in patients prior/post chemotherapy with healthy controls (***P ˂ 0.0001). Also there was signiﬁcant diﬀerence in patients prior and post chemotherapy
(***P ˂ 0.0001).
Proﬁle C shows the serum levels of CCL3 in AML patients prior and post chemotherapy (n = 25) alongside with healthy controls (n = 25). There was signiﬁcant
diﬀerence in patients prior chemotherapy with healthy controls (***P ˂ 0.0001). There was not signiﬁcant diﬀerence in patients post chemotherapy with healthy
controls (P ˃ 0.05). Also there was signiﬁcant diﬀerence in patients prior and post chemotherapy (**P ˂ 0.001).
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and resultantly the treatment response and prognosis. It has been found
that cytokines including CCL5 are involved in resistance to cytotoxic
agents through autocrine/paracrine signaling [24].
Considering the elevated levels of CCL5, CCL4, and CCL3 in AML
patients with monocytic diﬀerentiation, this elevation is associated
with poor prognosis. Hence we sought to carefully look if the ﬁrst phase
of chemotherapy is able to suppress these chemokines?
Our data indicated a striking diﬀerence in the pattern of chemokines
levels post the ﬁrst stage of chemotherapy; (7 + 3) current che-
motherapy regimen in patients suﬀering from AML with monocytic
diﬀerentiation. To the best of our knowledge, this study is very novel
because this is the ﬁrst study which has addressed a fundamental role
for CCL3-CCL4-CCL5/CCR5 axes in AML patients prior/post-che-
motherapy. Thus, there exists a gap of information in this ﬁeld. As we
have demonstrated, only CCL3 has returned to its basal level when
compared to healthy subjects and CCL5, CCL4 have been decreased but
have not backed to the basal level and they are still high in the serum
compared to the healthy control group. Thus, it probably could be
concluded that chemotherapy has not been completely able to inhibit
the expression of CCL5 and CCL4 chemokines (Fig. 4).
Thus, ﬁrstly, Chemotherapy caused secretion of various in-
ﬂammatory cytokines including CCL5 by diﬀerent tumor and immune
cell lines [24].
Secondly, production of these chemokines is probably related to the
regulatory eﬀects of G-CSF (granulocytic- colony stimulating factor)
which is consumed by the AML patients for recovery of their immune
system post-chemotherapy and the stimulate cytokines production
[25]. Also it can be due to changes in adaptive immune cells in AML
patients post chemotherapy [15].
In one study, chemotherapy for ALL, due to B.M damage, func-
tionally deregulates stromal cells of bone marrow and reduces CCL3
[26]. Thus, chemotherapy may be the cause of CCL3 depletion in our
study. In other words, Chemotherapy caused secretion of various in-
ﬂammatory cytokines including CCL5 and the cause of CCL3 depletion.
Overall, the role of chemokines in AML and its etiology, patho-
genesis and treatment is a very complex topic, and more studies are
deserved to at least, in part clarify the role of chemokine network in
treatment of AML. It is also important to look at the expression of these
chemokines at the mRNA level and also at their down and upstream
gene targets both prior and post-chemotherapy to achieve a better
understanding of the molecular basis of the AML and its response to
treatment. More attention needs to also be paid to evaluate the role of
patient's cytogenetic in chemokine expression.
5. Conclusion
Our data indicated that chemotherapy has not been completely able
to inhibit CCL5 and CCL4 chemokines in AML patients with monocytic
diﬀerentiation. In conclusion, taken together in an overall view, our
ﬁndings in harmony with previous studies suggest that inhibition of
chemokines expression along with chemotherapy in AML patients with
monocytic diﬀerentiation may aid therapy by either reducing the
duration of treatment, decreasing the dose of chemotherapy drugs, or
even preventing the relapse of the disease in patients.
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